(Q33962867)

30 July 2017

Environmental lead exposure and urate excretion in the general population (English)

1 reference

30 July 2017

Ja-Liang Lin

1

1 reference

30 July 2017

Dan-Tzu Tan

series ordinal

2

1 reference

30 July 2017

Huei-Hong Ho

series ordinal

3

1 reference

30 July 2017

Chun-Chen Yu

series ordinal

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

American Journal of Medicine

30 July 2017

1 reference

30 July 2017

113

1 reference

30 July 2017

7

1 reference

30 July 2017

563-568

1 reference

Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Detection and treatment of occupational lead nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Hyperuricemia and gout. Classification, complications and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

The relationship between blood lead levels and blood pressure and its cardiovascular risk implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Impairment of renal function with increasing blood lead concentrations in the general population. The Cadmibel Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Environmental lead exposure and progressive renal insufficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Blood lead concentration, blood pressure, and renal function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Renal insufficiency associated with excessive lead exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

The relationship of serum uric acid to subclinical blood lead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Preliminary criteria for the classification of the acute arthritis of primary gout

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Urinary nitrogen output as a validity test in dietary surveys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Analytical reviews in clinical biochemistry: the estimation of creatinine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Problems associated with the measurement of uric acid using two enzyme-mediated reaction systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Diminished renal urate secretion per nephron as a basis for primary gout.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Urinary lead excretion in uremic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Disappearance of Immune Deposits with EDTA Chelation Therapy in a Case of IgA Nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Lead chelation therapy and urate excretion in patients with chronic renal diseases and gout

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Purine metabolism in patients with gout: the role of lead

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Lead nephropathy, gout, and hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

The safety of the EDTA lead-mobilization test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency. A randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Experimental model of lead nephropathy. II. Effect of removal from lead exposure and chelation treatment with dimercaptosuccinic acid (DMSA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

The Relative Contributions of Tubular Reabsorption and Secretion to Urate Excretion in Lead Nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Endothelium-derived relaxing and contracting factors: perspectives in nephrology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Increased nitric oxide inactivation by reactive oxygen species in lead-induced hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

Lead-induced hypertension. II. Response to sequential infusions of L-arginine, superoxide dismutase, and nitroprusside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901296-2

10.1016/S0002-9343(02)01296-2

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference